id
stringlengths 7
11
| context
stringlengths 24
527
| is_mult_event
bool 2
classes | annotations
list |
|---|---|---|---|
23552010_2 | This is a case report involving a patient who was treated with topical 5-FU cream and subsequently developed a severe case of angioedema. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"developed\"]], \"start\": [[99]], \"entity_id\": [\"T6\"]}, \"Subject\": {\"text\": [[\"a patient\"]], \"start\": [[32]], \"entity_id\": [\"T4\"]}, \"Treatment\": {\"text\": [[\"topical 5-FU cream\"]], \"start\": [[63]], \"entity_id\": [\"T5\"], \"Route\": {\"text\": [[\"topical\"]], \"start\": [[63]], \"entity_id\": [\"T8\"]}, \"Drug\": {\"text\": [[\"5-FU\"]], \"start\": [[71]], \"entity_id\": [\"T9\"]}}, \"Effect\": {\"text\": [[\"a severe case of angioedema\"]], \"start\": [[109]], \"entity_id\": [\"T7\"]}}"
}
]
}
] |
10555917_2 | Cessation of D-Pen and the start of corticosteroid therapy were followed by recovery from bicytopenia. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Potential_therapeutic_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Potential_therapeutic_event\", \"Trigger\": {\"text\": [[\"followed\"]], \"start\": [[64]], \"entity_id\": [\"T5\"]}, \"Treatment\": {\"text\": [[\"Cessation of D-Pen and the start of corticosteroid therapy\"]], \"start\": [[0]], \"entity_id\": [\"T4\"], \"Drug\": {\"text\": [[\"D-Pen\"], [\"corticosteroid\"]], \"start\": [[13], [36]], \"entity_id\": [\"T3\", \"T7\"]}, \"Disorder\": {\"text\": [[\"bicytopenia\"]], \"start\": [[90]], \"entity_id\": [\"T1\"]}}, \"Effect\": {\"text\": [[\"recovery from bicytopenia\"]], \"start\": [[76]], \"entity_id\": [\"T6\"]}}"
}
]
}
] |
21751666_3 | Prevention of infection by immunization, together with early recognition and prompt antiviral treatment are critical. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Potential_therapeutic_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Potential_therapeutic_event\", \"Trigger\": {\"text\": [[\"Prevention\"]], \"start\": [[0]], \"entity_id\": [\"T6\"]}, \"Treatment\": {\"text\": [[\"immunization, together with early recognition and prompt antiviral treatment\"]], \"start\": [[27]], \"entity_id\": [\"T8\"], \"Disorder\": {\"text\": [[\"infection\"]], \"start\": [[14]], \"entity_id\": [\"T7\"]}}}"
}
]
}
] |
10879669_1 | A case of normotensive scleroderma renal crisis after high-dose methylprednisolone treatment. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"after\"]], \"start\": [[48]], \"entity_id\": [\"T4\"]}, \"Effect\": {\"text\": [[\"normotensive scleroderma renal crisis\"]], \"start\": [[10]], \"entity_id\": [\"T3\"]}, \"Treatment\": {\"text\": [[\"high-dose methylprednisolone treatment\"]], \"start\": [[54]], \"entity_id\": [\"T5\"], \"Dosage\": {\"text\": [[\"high-dose\"]], \"start\": [[54]], \"entity_id\": [\"T7\"]}, \"Drug\": {\"text\": [[\"methylprednisolone\"]], \"start\": [[64]], \"entity_id\": [\"T8\"]}}, \"Subject\": {\"text\": [[\"A case\"]], \"start\": [[0]], \"entity_id\": [\"T6\"]}}"
}
]
}
] |
16411025_3 | OBJECTIVES: A delayed stroke-like leukoencephalopathy has been observed in patients receiving methotrexate (MTX) for childhood leukemia. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"has been observed\"]], \"start\": [[54]], \"entity_id\": [\"T4\"]}, \"Effect\": {\"text\": [[\"delayed stroke-like leukoencephalopathy\"]], \"start\": [[14]], \"entity_id\": [\"T5\"]}, \"Treatment\": {\"text\": [[\"methotrexate (MTX)\"]], \"start\": [[94]], \"entity_id\": [\"T6\"], \"Drug\": {\"text\": [[\"methotrexate\"]], \"start\": [[94]], \"entity_id\": [\"T9\"]}, \"Disorder\": {\"text\": [[\"childhood leukemia\"]], \"start\": [[117]], \"entity_id\": [\"T10\"]}}, \"Subject\": {\"text\": [[\"patients\", \"childhood leukemia\"]], \"start\": [[75, 117]], \"entity_id\": [\"T8\"], \"Age\": {\"text\": [[\"childhood\"]], \"start\": [[117]], \"entity_id\": [\"T7\"]}}}"
}
]
}
] |
25538343_1 | Duloxetine-induced hyponatremia in an elderly patient treated with thiazide diuretics. | true | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"induced\"]], \"start\": [[11]], \"entity_id\": [\"T10\"]}, \"Treatment\": {\"text\": [[\"Duloxetine\"]], \"start\": [[0]], \"entity_id\": [\"T9\"], \"Drug\": {\"text\": [[\"Duloxetine\"], [\"thiazide diuretics\"]], \"start\": [[0], [67]], \"entity_id\": [\"T13\", \"T15\"]}, \"Combination\": [{\"event_id\": \"E2\", \"event_type\": \"Combination\", \"Trigger\": {\"text\": [[\"with\"]], \"start\": [[62]], \"entity_id\": [\"T12\"]}, \"Drug\": {\"text\": [[\"thiazide diuretics\"], [\"Duloxetine\"]], \"start\": [[67], [0]], \"entity_id\": [\"T15\", \"T13\"]}}]}, \"Effect\": {\"text\": [[\"hyponatremia\"]], \"start\": [[19]], \"entity_id\": [\"T11\"]}, \"Subject\": {\"text\": [[\"an elderly patient treated with thiazide diuretics\"]], \"start\": [[35]], \"entity_id\": [\"T7\"], \"Age\": {\"text\": [[\"elderly\"]], \"start\": [[38]], \"entity_id\": [\"T8\"]}}}"
}
]
}
] |
16623611_2 | The following is a case report analysis intended to draw attention to the need for better care coordination by describing the observed relationship of olanzapine to metabolic changes manifested as uncontrolled diabetes mellitus and weight gain. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"relationship\"]], \"start\": [[135]], \"entity_id\": [\"T5\"]}, \"Treatment\": {\"text\": [[\"olanzapine\"]], \"start\": [[151]], \"entity_id\": [\"T6\"], \"Drug\": {\"text\": [[\"olanzapine\"]], \"start\": [[151]], \"entity_id\": [\"T8\"]}}, \"Effect\": {\"text\": [[\"metabolic changes manifested as uncontrolled diabetes mellitus and weight gain\"]], \"start\": [[165]], \"entity_id\": [\"T7\"]}}"
}
]
}
] |
10466445_2 | Arsenic trioxide has recently been introduced as a promising new agent to treat refractory acute promyelocytic leukemia (APL). | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Potential_therapeutic_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Potential_therapeutic_event\", \"Trigger\": {\"text\": [[\"treat\"]], \"start\": [[74]], \"entity_id\": [\"T6\"]}, \"Treatment\": {\"text\": [[\"Arsenic trioxide\"]], \"start\": [[0]], \"entity_id\": [\"T5\"], \"Drug\": {\"text\": [[\"Arsenic trioxide\"]], \"start\": [[0]], \"entity_id\": [\"T8\"]}, \"Disorder\": {\"text\": [[\"refractory acute promyelocytic leukemia\"]], \"start\": [[80]], \"entity_id\": [\"T9\"]}}}"
}
]
}
] |
10779995_1 | Although the t-AML developed following oral etoposide therapy, the child had previously received high-dose, multiagent chemotherapy, and rearrangement of the MLL gene was not demonstrated. | true | [
{
"events": [
{
"event_id": "E2",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E2\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"developed\"]], \"start\": [[19]], \"entity_id\": [\"T7\"]}, \"Subject\": {\"text\": [[\"the child\"]], \"start\": [[63]], \"entity_id\": [\"T3\"], \"Age\": {\"text\": [[\"child\"]], \"start\": [[67]], \"entity_id\": [\"T6\"]}}, \"Effect\": {\"text\": [[\"the t-AML\"]], \"start\": [[9]], \"entity_id\": [\"T4\"]}, \"Treatment\": {\"text\": [[\"oral etoposide therapy\", \"high-dose, multiagent chemotherapy\"]], \"start\": [[39, 97]], \"entity_id\": [\"T5\"], \"Drug\": {\"text\": [[\"etoposide\"], [\"chemotherapy\"]], \"start\": [[44], [119]], \"entity_id\": [\"T8\", \"T11\"]}, \"Route\": {\"text\": [[\"oral\"]], \"start\": [[39]], \"entity_id\": [\"T9\"]}, \"Dosage\": {\"text\": [[\"high-dose\"]], \"start\": [[97]], \"entity_id\": [\"T13\"]}, \"Combination\": [{\"event_id\": \"E1\", \"event_type\": \"Combination\", \"Trigger\": {\"text\": [[\"received\"]], \"start\": [[88]], \"entity_id\": [\"T10\"]}, \"Drug\": {\"text\": [[\"chemotherapy\"], [\"etoposide\"]], \"start\": [[119], [44]], \"entity_id\": [\"T11\", \"T8\"]}}]}}"
}
]
}
] |
15107195_2 | Heat stroke in schizophrenia during clozapine treatment: rapid recognition and management. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"during\"]], \"start\": [[29]], \"entity_id\": [\"T3\"]}, \"Effect\": {\"text\": [[\"Heat stroke\"]], \"start\": [[0]], \"entity_id\": [\"T4\"]}, \"Treatment\": {\"text\": [[\"clozapine\"]], \"start\": [[36]], \"entity_id\": [\"T6\"], \"Disorder\": {\"text\": [[\"schizophrenia\"]], \"start\": [[15]], \"entity_id\": [\"T5\"]}, \"Drug\": {\"text\": [[\"clozapine\"]], \"start\": [[36]], \"entity_id\": [\"T7\"]}}}"
}
]
}
] |
25957434_4 | The same symptoms recurred few days after taking nitrendipine. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"taking\"]], \"start\": [[42]], \"entity_id\": [\"T5\"]}, \"Treatment\": {\"text\": [[\"nitrendipine\", \"few days after\"]], \"start\": [[49, 27]], \"entity_id\": [\"T4\"], \"Time_elapsed\": {\"text\": [[\"few days afte\"]], \"start\": [[27]], \"entity_id\": [\"T7\"]}, \"Drug\": {\"text\": [[\"nitrendipine\"]], \"start\": [[49]], \"entity_id\": [\"T8\"]}}, \"Effect\": {\"text\": [[\"same symptoms\"]], \"start\": [[4]], \"entity_id\": [\"T6\"]}}"
}
]
}
] |
16062101_3 | The authors report two cases of acute dystonic reactions (ADRs) as a side effect of lamivudine. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"effect\"]], \"start\": [[74]], \"entity_id\": [\"T8\"]}, \"Subject\": {\"text\": [[\"two cases\"]], \"start\": [[19]], \"entity_id\": [\"T5\"], \"Population\": {\"text\": [[\"two\"]], \"start\": [[19]], \"entity_id\": [\"T9\"]}}, \"Effect\": {\"text\": [[\"acute dystonic reactions (ADRs)\"]], \"start\": [[32]], \"entity_id\": [\"T6\"]}, \"Treatment\": {\"text\": [[\"lamivudine\"]], \"start\": [[84]], \"entity_id\": [\"T7\"], \"Drug\": {\"text\": [[\"lamivudine\"]], \"start\": [[84]], \"entity_id\": [\"T10\"]}}}"
}
]
}
] |
12751276_1 | Isoniazid-induced anaphylaxis. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"induced\"]], \"start\": [[10]], \"entity_id\": [\"T4\"]}, \"Treatment\": {\"text\": [[\"Isoniazid\"]], \"start\": [[0]], \"entity_id\": [\"T5\"], \"Drug\": {\"text\": [[\"Isoniazid\"]], \"start\": [[0]], \"entity_id\": [\"T7\"]}}, \"Effect\": {\"text\": [[\"anaphylaxis\"]], \"start\": [[18]], \"entity_id\": [\"T6\"]}}"
}
]
}
] |
18067642_3 | Histopathology of the thyroid in amiodarone-induced hypothyroidism. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"induced\"]], \"start\": [[44]], \"entity_id\": [\"T4\"]}, \"Treatment\": {\"text\": [[\"amiodarone\"]], \"start\": [[33]], \"entity_id\": [\"T3\"], \"Drug\": {\"text\": [[\"amiodarone\"]], \"start\": [[33]], \"entity_id\": [\"T6\"]}}, \"Effect\": {\"text\": [[\"hypothyroidism\"]], \"start\": [[52]], \"entity_id\": [\"T5\"]}}"
}
]
}
] |
15300114_1 | Deepening of lid sulcus from topical bimatoprost therapy. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"from\"]], \"start\": [[24]], \"entity_id\": [\"T4\"]}, \"Effect\": {\"text\": [[\"Deepening of lid sulcus\"]], \"start\": [[0]], \"entity_id\": [\"T3\"]}, \"Treatment\": {\"text\": [[\"bimatoprost\"]], \"start\": [[37]], \"entity_id\": [\"T5\"], \"Drug\": {\"text\": [[\"bimatoprost\"]], \"start\": [[37]], \"entity_id\": [\"T6\"]}}}"
}
]
}
] |
2979256_2 | Gastro-oesophageal reflux associated with nifedipine. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"associated\"]], \"start\": [[26]], \"entity_id\": [\"T4\"]}, \"Effect\": {\"text\": [[\"Gastro-oesophageal reflux\"]], \"start\": [[0]], \"entity_id\": [\"T3\"]}, \"Treatment\": {\"text\": [[\"nifedipine\"]], \"start\": [[42]], \"entity_id\": [\"T5\"], \"Drug\": {\"text\": [[\"nifedipine\"]], \"start\": [[42]], \"entity_id\": [\"T6\"]}}}"
}
]
}
] |
7919557_1 | CASE SUMMARY: A 68-year-old woman developed a dry, irritating cough within one month of starting quinapril therapy for the treatment of essential hypertension. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"starting\"]], \"start\": [[88]], \"entity_id\": [\"T3\"]}, \"Treatment\": {\"text\": [[\"quinapril therapy\"]], \"start\": [[97]], \"entity_id\": [\"T4\"], \"Time_elapsed\": {\"text\": [[\"within one month\"]], \"start\": [[68]], \"entity_id\": [\"T9\"]}, \"Drug\": {\"text\": [[\"quinapril\"]], \"start\": [[97]], \"entity_id\": [\"T10\"]}, \"Disorder\": {\"text\": [[\"essential hypertension\"]], \"start\": [[136]], \"entity_id\": [\"T12\"]}}, \"Subject\": {\"text\": [[\"A 68-year-old woman\"]], \"start\": [[14]], \"entity_id\": [\"T5\"], \"Age\": {\"text\": [[\"68-year-old\"]], \"start\": [[16]], \"entity_id\": [\"T7\"]}, \"Gender\": {\"text\": [[\"woman\"]], \"start\": [[28]], \"entity_id\": [\"T8\"]}}, \"Effect\": {\"text\": [[\"a dry, irritating cough\"]], \"start\": [[44]], \"entity_id\": [\"T6\"]}}"
}
]
}
] |
19567656_4 | Sertraline-induced rhabdomyolysis in an elderly patient with dementia and comorbidities. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"induced\"]], \"start\": [[11]], \"entity_id\": [\"T4\"]}, \"Treatment\": {\"text\": [[\"Sertraline\"]], \"start\": [[0]], \"entity_id\": [\"T3\"], \"Drug\": {\"text\": [[\"Sertraline\"]], \"start\": [[0]], \"entity_id\": [\"T9\"]}}, \"Effect\": {\"text\": [[\"rhabdomyolysis\"]], \"start\": [[19]], \"entity_id\": [\"T5\"]}, \"Subject\": {\"text\": [[\"an elderly patient with dementia and comorbidities\"]], \"start\": [[37]], \"entity_id\": [\"T6\"], \"Age\": {\"text\": [[\"elderly\"]], \"start\": [[40]], \"entity_id\": [\"T7\"]}, \"Disorder\": {\"text\": [[\"dementia\"], [\"comorbidities\"]], \"start\": [[61], [74]], \"entity_id\": [\"T8\", \"T1\"]}}}"
}
]
}
] |
11431864_1 | After the dose of methylprednisolone was reduced from 40 mg to 20 mg i.v. q6h and shifted to other anti-asthma treatment by procaterol metered dose inhaler via spacer, the psychotic reaction disappeared a few hours later. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Potential_therapeutic_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Potential_therapeutic_event\", \"Trigger\": {\"text\": [[\"disappeared\"]], \"start\": [[191]], \"entity_id\": [\"T3\"]}, \"Treatment\": {\"text\": [[\"After the dose of methylprednisolone was reduced from 40 mg to 20 mg i.v. q6h and shifted to other anti-asthma treatment by procaterol metered dose inhaler via spacer\", \"a few hours later\"]], \"start\": [[0, 203]], \"entity_id\": [\"T5\"], \"Disorder\": {\"text\": [[\"psychotic reaction\"]], \"start\": [[172]], \"entity_id\": [\"T4\"]}, \"Time_elapsed\": {\"text\": [[\"a few hours\"]], \"start\": [[203]], \"entity_id\": [\"T6\"]}, \"Drug\": {\"text\": [[\"methylprednisolone\"]], \"start\": [[18]], \"entity_id\": [\"T7\"]}, \"Dosage\": {\"text\": [[\"reduced from 40 mg to 20 mg i.v. q6h\"]], \"start\": [[41]], \"entity_id\": [\"T8\"]}, \"Route\": {\"text\": [[\"spacer\"]], \"start\": [[160]], \"entity_id\": [\"T9\"]}}}"
}
]
}
] |
16649344_3 | Sirolimus works differently from the immunosuppressants currently available, and except for increased lipid levels, the adverse reaction profile of sirolimus does not appear to overlap to any great extent with that associated with cyclosporine or tacrolimus. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"for\"]], \"start\": [[88]], \"entity_id\": [\"T9\"]}, \"Effect\": {\"text\": [[\"increased lipid levels\"]], \"start\": [[92]], \"entity_id\": [\"T7\"]}, \"Treatment\": {\"text\": [[\"Sirolimus works differently from the immunosuppressants currently available\"]], \"start\": [[0]], \"entity_id\": [\"T8\"], \"Drug\": {\"text\": [[\"Sirolimus\"], [\"immunosuppressants\"], [\"sirolimus\"], [\"cyclosporine\"], [\"tacrolimus\"]], \"start\": [[0], [37], [148], [231], [247]], \"entity_id\": [\"T10\", \"T11\", \"T12\", \"T13\", \"T14\"]}}}"
}
]
}
] |
21512888_7 | Patient was on warfarin for a prior deep venous thrombosis. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Potential_therapeutic_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Potential_therapeutic_event\", \"Trigger\": {\"text\": [[\"for\"]], \"start\": [[24]], \"entity_id\": [\"T6\"]}, \"Treatment\": {\"text\": [[\"warfarin\"]], \"start\": [[15]], \"entity_id\": [\"T5\"], \"Disorder\": {\"text\": [[\"a prior deep venous thrombosis\"]], \"start\": [[28]], \"entity_id\": [\"T7\"]}, \"Drug\": {\"text\": [[\"warfarin\"]], \"start\": [[15]], \"entity_id\": [\"T9\"]}}}"
}
]
}
] |
15729090_1 | Quetiapine-induced myoclonus. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"induced\"]], \"start\": [[11]], \"entity_id\": [\"T5\"]}, \"Treatment\": {\"text\": [[\"Quetiapine\"]], \"start\": [[0]], \"entity_id\": [\"T4\"], \"Drug\": {\"text\": [[\"Quetiapine\"]], \"start\": [[0]], \"entity_id\": [\"T7\"]}}, \"Effect\": {\"text\": [[\"myoclonus\"]], \"start\": [[19]], \"entity_id\": [\"T6\"]}}"
}
]
}
] |
3391110_1 | Dyspnea possibly associated with controlled-release morphine sulfate tablets. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"associated\"]], \"start\": [[17]], \"entity_id\": [\"T4\"]}, \"Effect\": {\"text\": [[\"Dyspnea\"]], \"start\": [[0]], \"entity_id\": [\"T3\"]}, \"Treatment\": {\"text\": [[\"controlled-release morphine sulfate tablets\"]], \"start\": [[33]], \"entity_id\": [\"T5\"], \"Drug\": {\"text\": [[\"morphine sulfate\"]], \"start\": [[52]], \"entity_id\": [\"T7\"]}, \"Route\": {\"text\": [[\"tablets\"]], \"start\": [[69]], \"entity_id\": [\"T8\"]}, \"Dosage\": {\"text\": [[\"controlled-release\"]], \"start\": [[33]], \"entity_id\": [\"T9\"]}}, \"Speculated\": {\"text\": [[\"possibly\"]], \"start\": [[8]], \"entity_id\": [\"T6\"], \"value\": true}}"
}
]
}
] |
7496198_6 | The incidence of ARE suddenly exceeded 10% of the patients treated by melarsoprol during August 1992 and September 1993. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"by\"]], \"start\": [[67]], \"entity_id\": [\"T7\"]}, \"Treatment\": {\"text\": [[\"melarsoprol\"]], \"start\": [[70]], \"entity_id\": [\"T4\"], \"Drug\": {\"text\": [[\"melarsoprol\"]], \"start\": [[70]], \"entity_id\": [\"T8\"]}, \"Duration\": {\"text\": [[\"August 1992 and September 1993\"]], \"start\": [[89]], \"entity_id\": [\"T9\"]}}, \"Subject\": {\"text\": [[\"patients\"]], \"start\": [[50]], \"entity_id\": [\"T5\"]}, \"Effect\": {\"text\": [[\"ARE\"]], \"start\": [[17]], \"entity_id\": [\"T6\"]}}"
}
]
}
] |
426502_1 | A patient with disseminated herpes zoster developed a syndrome of inappropriate antidiuretic hormone and profound hyponatremia secondary to the administration of adenine arabinoside. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"developed\"]], \"start\": [[42]], \"entity_id\": [\"T5\"]}, \"Treatment\": {\"text\": [[\"adenine arabinoside\"]], \"start\": [[162]], \"entity_id\": [\"T6\"], \"Drug\": {\"text\": [[\"adenine arabinoside\"]], \"start\": [[162]], \"entity_id\": [\"T10\"]}, \"Disorder\": {\"text\": [[\"disseminated herpes zoster\"]], \"start\": [[15]], \"entity_id\": [\"T11\"]}}, \"Effect\": {\"text\": [[\"syndrome of inappropriate antidiuretic hormone and profound hyponatremia\"]], \"start\": [[54]], \"entity_id\": [\"T7\"]}, \"Subject\": {\"text\": [[\"A patient with disseminated herpes zoster\"]], \"start\": [[0]], \"entity_id\": [\"T8\"]}, \"Severity\": {\"text\": [[\"profound\"]], \"start\": [[105]], \"entity_id\": [\"T12\"], \"value\": \"High\"}}"
}
]
}
] |
2147700_1 | One patient with systemic lupus erythematosus developed erythema multiforme after taking griseofulvin. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"after\"]], \"start\": [[76]], \"entity_id\": [\"T4\"]}, \"Subject\": {\"text\": [[\"One patient with systemic lupus erythematosus\"]], \"start\": [[0]], \"entity_id\": [\"T3\"], \"Population\": {\"text\": [[\"One\"]], \"start\": [[0]], \"entity_id\": [\"T7\"]}, \"Disorder\": {\"text\": [[\"systemic lupus erythematosus\"]], \"start\": [[17]], \"entity_id\": [\"T8\"]}}, \"Effect\": {\"text\": [[\"erythema multiforme\"]], \"start\": [[56]], \"entity_id\": [\"T5\"]}, \"Treatment\": {\"text\": [[\"griseofulvin\"]], \"start\": [[89]], \"entity_id\": [\"T6\"], \"Drug\": {\"text\": [[\"griseofulvin\"]], \"start\": [[89]], \"entity_id\": [\"T9\"]}}}"
}
]
}
] |
19949685_4 | We report a rare case of colonic mucosal necrosis following Kalimate (calcium polystryrene sulfonate), an analogue of Kayexalate without sorbitol in a 34-yr-old man. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"following\"]], \"start\": [[50]], \"entity_id\": [\"T8\"]}, \"Subject\": {\"text\": [[\"a 34-yr-old man\"]], \"start\": [[149]], \"entity_id\": [\"T5\"], \"Age\": {\"text\": [[\"34-yr-old\"]], \"start\": [[151]], \"entity_id\": [\"T9\"]}, \"Gender\": {\"text\": [[\"man\"]], \"start\": [[161]], \"entity_id\": [\"T10\"]}}, \"Effect\": {\"text\": [[\"colonic mucosal necrosis\"]], \"start\": [[25]], \"entity_id\": [\"T6\"]}, \"Treatment\": {\"text\": [[\"Kalimate (calcium polystryrene sulfonate), an analogue of Kayexalate without sorbitol\"]], \"start\": [[60]], \"entity_id\": [\"T7\"], \"Drug\": {\"text\": [[\"Kalimate\"], [\"(calcium polystryrene sulfonate)\"], [\"Kayexalate\"]], \"start\": [[60], [69], [118]], \"entity_id\": [\"T11\", \"T12\", \"T13\"]}}}"
}
]
}
] |
18379937_1 | Bilateral anterior uveitis associated with clomiphene citrate. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"associated\"]], \"start\": [[27]], \"entity_id\": [\"T4\"]}, \"Effect\": {\"text\": [[\"Bilateral anterior uveitis\"]], \"start\": [[0]], \"entity_id\": [\"T3\"]}, \"Treatment\": {\"text\": [[\"clomiphene citrate\"]], \"start\": [[43]], \"entity_id\": [\"T5\"], \"Drug\": {\"text\": [[\"clomiphene citrate\"]], \"start\": [[43]], \"entity_id\": [\"T6\"]}}}"
}
]
}
] |
15479299_1 | Progressive anemia following combination therapy with interferon-alpha and interleukin-2 in a patient with metastatic renal cell carcinoma. | true | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"following\"]], \"start\": [[19]], \"entity_id\": [\"T7\"]}, \"Effect\": {\"text\": [[\"Progressive anemia\"]], \"start\": [[0]], \"entity_id\": [\"T4\"]}, \"Subject\": {\"text\": [[\"a patient with metastatic renal cell carcinoma\"]], \"start\": [[92]], \"entity_id\": [\"T6\"]}, \"Treatment\": {\"text\": [[\"combination therapy with interferon-alpha and interleukin-2\"]], \"start\": [[29]], \"entity_id\": [\"T5\"], \"Disorder\": {\"text\": [[\"metastatic renal cell carcinoma\"]], \"start\": [[107]], \"entity_id\": [\"T8\"]}, \"Drug\": {\"text\": [[\"interferon-alpha\"], [\"interleukin-2\"]], \"start\": [[54], [75]], \"entity_id\": [\"T9\", \"T10\"]}, \"Combination\": [{\"event_id\": \"E2\", \"event_type\": \"Combination\", \"Trigger\": {\"text\": [[\"combination\"]], \"start\": [[29]], \"entity_id\": [\"T11\"]}, \"Drug\": {\"text\": [[\"interferon-alpha\"], [\"interleukin-2\"]], \"start\": [[54], [75]], \"entity_id\": [\"T9\", \"T10\"]}}]}}"
}
]
}
] |
2595431_2 | Metoclopramide-induced parkinsonism. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"induced\"]], \"start\": [[15]], \"entity_id\": [\"T4\"]}, \"Treatment\": {\"text\": [[\"Metoclopramide\"]], \"start\": [[0]], \"entity_id\": [\"T3\"], \"Drug\": {\"text\": [[\"Metoclopramide\"]], \"start\": [[0]], \"entity_id\": [\"T6\"]}}, \"Effect\": {\"text\": [[\"parkinsonism\"]], \"start\": [[23]], \"entity_id\": [\"T5\"]}}"
}
]
}
] |
8461228_1 | A 12 year old patient with atrial flutter is presented, in whom intravenous adenosine was followed by acceleration of the heart rate to a potentially dangerous arrhythmia. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"followed by\"]], \"start\": [[90]], \"entity_id\": [\"T10\"]}, \"Subject\": {\"text\": [[\"12 year old patient with atrial flutter\"]], \"start\": [[2]], \"entity_id\": [\"T5\"], \"Age\": {\"text\": [[\"12 year old\"]], \"start\": [[2]], \"entity_id\": [\"T11\"]}}, \"Treatment\": {\"text\": [[\"intravenous adenosine\"]], \"start\": [[64]], \"entity_id\": [\"T7\"], \"Drug\": {\"text\": [[\"adenosine\"]], \"start\": [[76]], \"entity_id\": [\"T12\"]}, \"Route\": {\"text\": [[\"intravenous\"]], \"start\": [[64]], \"entity_id\": [\"T13\"]}, \"Disorder\": {\"text\": [[\"atrial flutter\"]], \"start\": [[27]], \"entity_id\": [\"T14\"]}}, \"Effect\": {\"text\": [[\"acceleration of the heart rate to a potentially dangerous arrhythmia\"]], \"start\": [[102]], \"entity_id\": [\"T9\"]}, \"Speculated\": {\"text\": [[\"potentially\"]], \"start\": [[138]], \"entity_id\": [\"T8\"], \"value\": true}}"
}
]
}
] |
17873198_3 | Similar to reports in patients receiving gefitinib, those with pathologic findings of UIP on resected lung specimens or known pulmonary fibrosis may be at particular risk for erlotinib pulmonary toxicity. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"receiving\"]], \"start\": [[31]], \"entity_id\": [\"T5\"]}, \"Treatment\": {\"text\": [[\"gefitinib\"]], \"start\": [[41]], \"entity_id\": [\"T6\"], \"Drug\": {\"text\": [[\"gefitinib\"]], \"start\": [[41]], \"entity_id\": [\"T9\"]}}, \"Subject\": {\"text\": [[\"patients\"]], \"start\": [[22]], \"entity_id\": [\"T7\"]}, \"Effect\": {\"text\": [[\"erlotinib pulmonary toxicity.\"]], \"start\": [[175]], \"entity_id\": [\"T8\"]}}"
}
]
}
] |
11144696_4 | Eleven days after increase of the trimipramine dosage to 100 mg/d, she was hospitalized because of seizures suggesting a secondary generalized grand-mal episode. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"hospitalized\"]], \"start\": [[75]], \"entity_id\": [\"T7\"]}, \"Treatment\": {\"text\": [[\"Eleven days after increase of the trimipramine dosage to 100 mg/d\"]], \"start\": [[0]], \"entity_id\": [\"T5\"], \"Time_elapsed\": {\"text\": [[\"Eleven days\"]], \"start\": [[0]], \"entity_id\": [\"T10\"]}, \"Dosage\": {\"text\": [[\"100 mg/d\"]], \"start\": [[57]], \"entity_id\": [\"T11\"]}, \"Drug\": {\"text\": [[\"trimipramine\"]], \"start\": [[34]], \"entity_id\": [\"T12\"]}}, \"Subject\": {\"text\": [[\"she\"]], \"start\": [[67]], \"entity_id\": [\"T6\"], \"Gender\": {\"text\": [[\"she\"]], \"start\": [[67]], \"entity_id\": [\"T9\"]}}, \"Effect\": {\"text\": [[\"seizures suggesting a secondary generalized grand-mal episode\"]], \"start\": [[99]], \"entity_id\": [\"T8\"]}}"
}
]
}
] |
19707032_3 | AIM: To report a patient with diabetic rubeosis who suffered from acute retinal ischemic change and stroke after intravitreal injection of bevacizumab. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"suffered\"]], \"start\": [[52]], \"entity_id\": [\"T10\"]}, \"Subject\": {\"text\": [[\"patient with diabetic rubeosis\"]], \"start\": [[17]], \"entity_id\": [\"T5\"]}, \"Effect\": {\"text\": [[\"acute retinal ischemic change and stroke\"]], \"start\": [[66]], \"entity_id\": [\"T7\"]}, \"Treatment\": {\"text\": [[\"intravitreal injection of bevacizumab\"]], \"start\": [[113]], \"entity_id\": [\"T9\"], \"Disorder\": {\"text\": [[\"diabetic rubeosis\"]], \"start\": [[30]], \"entity_id\": [\"T11\"]}, \"Drug\": {\"text\": [[\"bevacizumab\"]], \"start\": [[139]], \"entity_id\": [\"T8\"]}, \"Route\": {\"text\": [[\"intravitreal injection\"]], \"start\": [[113]], \"entity_id\": [\"T12\"]}}, \"Severity\": {\"text\": [[\"acute\"]], \"start\": [[66]], \"entity_id\": [\"T13\"], \"value\": \"High\"}}"
}
]
}
] |
11174414_1 | Stevens-Johnson syndrome caused by the antiretroviral drug nevirapine. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"caused by\"]], \"start\": [[25]], \"entity_id\": [\"T6\"]}, \"Effect\": {\"text\": [[\"Stevens-Johnson syndrome\"]], \"start\": [[0]], \"entity_id\": [\"T5\"]}, \"Treatment\": {\"text\": [[\"antiretroviral drug nevirapine\"]], \"start\": [[39]], \"entity_id\": [\"T7\"], \"Drug\": {\"text\": [[\"nevirapine\"]], \"start\": [[59]], \"entity_id\": [\"T8\"]}}}"
}
]
}
] |
9476721_2 | From these data, acute generalized dystonia with brainstem and thalamic lesions may occur in WD patients after an initial d-penicillamine therapy. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"after\"]], \"start\": [[105]], \"entity_id\": [\"T5\"]}, \"Treatment\": {\"text\": [[\"an initial d-penicillamine therapy\"]], \"start\": [[111]], \"entity_id\": [\"T6\"], \"Disorder\": {\"text\": [[\"WD\"]], \"start\": [[93]], \"entity_id\": [\"T9\"]}, \"Drug\": {\"text\": [[\"d-penicillamine\"]], \"start\": [[122]], \"entity_id\": [\"T10\"]}}, \"Subject\": {\"text\": [[\"WD patients\"]], \"start\": [[93]], \"entity_id\": [\"T7\"]}, \"Effect\": {\"text\": [[\"acute generalized dystonia with brainstem and thalamic lesions\"]], \"start\": [[17]], \"entity_id\": [\"T8\"]}, \"Speculated\": {\"text\": [[\"may occur\"]], \"start\": [[80]], \"entity_id\": [\"T11\"], \"value\": true}, \"Severity\": {\"text\": [[\"acute\"]], \"start\": [[17]], \"entity_id\": [\"T12\"], \"value\": \"High\"}}"
}
]
}
] |
20412003_2 | Although this combination agent has been associated with a hypersensitivity syndrome involving cutaneous skin eruptions, pediatric cases of TMP-SMX-induced hepatotoxicity are rare. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"induced\"]], \"start\": [[148]], \"entity_id\": [\"T8\"]}, \"Treatment\": {\"text\": [[\"TMP-SMX\"]], \"start\": [[140]], \"entity_id\": [\"T7\"], \"Drug\": {\"text\": [[\"TMP-SMX\"]], \"start\": [[140]], \"entity_id\": [\"T13\"]}}, \"Effect\": {\"text\": [[\"hepatotoxicity\"]], \"start\": [[156]], \"entity_id\": [\"T9\"]}, \"Subject\": {\"text\": [[\"pediatric cases\"]], \"start\": [[121]], \"entity_id\": [\"T10\"], \"Age\": {\"text\": [[\"pediatric\"]], \"start\": [[121]], \"entity_id\": [\"T12\"]}}}"
}
]
}
] |
21728158_4 | Drug resistant tuberculosis requires more complex and longer treatment with alternative substances. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Potential_therapeutic_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Potential_therapeutic_event\", \"Trigger\": {\"text\": [[\"requires\"]], \"start\": [[28]], \"entity_id\": [\"T5\"]}, \"Treatment\": {\"text\": [[\"complex and longer treatment with alternative substances\"]], \"start\": [[42]], \"entity_id\": [\"T6\"], \"Disorder\": {\"text\": [[\"Drug resistant tuberculosis\"]], \"start\": [[0]], \"entity_id\": [\"T4\"]}, \"Drug\": {\"text\": [[\"substances\"]], \"start\": [[88]], \"entity_id\": [\"T7\"]}, \"Duration\": {\"text\": [[\"complex and longer treatment\"]], \"start\": [[42]], \"entity_id\": [\"T8\"]}}}"
}
]
}
] |
7668127_1 | Intracranial haemorrhage from a meningioma in a patient receiving aspirin prophylaxis: a case report. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"in\"]], \"start\": [[43]], \"entity_id\": [\"T8\"]}, \"Effect\": {\"text\": [[\"Intracranial haemorrhage from a meningioma\"]], \"start\": [[0]], \"entity_id\": [\"T5\"]}, \"Subject\": {\"text\": [[\"a patient\"]], \"start\": [[46]], \"entity_id\": [\"T6\"]}, \"Treatment\": {\"text\": [[\"aspirin\"]], \"start\": [[66]], \"entity_id\": [\"T9\"], \"Drug\": {\"text\": [[\"aspirin\"]], \"start\": [[66]], \"entity_id\": [\"T7\"]}}}"
}
]
}
] |
10395123_3 | The objective of this report is to describe a case of fixed drug eruption that occurred during omeprazole treatment. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"occurred\"]], \"start\": [[79]], \"entity_id\": [\"T4\"]}, \"Effect\": {\"text\": [[\"fixed drug eruption\"]], \"start\": [[54]], \"entity_id\": [\"T3\"]}, \"Treatment\": {\"text\": [[\"during omeprazole treatment\"]], \"start\": [[88]], \"entity_id\": [\"T5\"], \"Drug\": {\"text\": [[\"omeprazole\"]], \"start\": [[95]], \"entity_id\": [\"T6\"]}}}"
}
]
}
] |
10803790_2 | Case 2: A 43-year-old male alcoholic remained completely abstinent with cyanamide treatment for 5 years and complained of general fatigue. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"complained\"]], \"start\": [[108]], \"entity_id\": [\"T5\"]}, \"Subject\": {\"text\": [[\"A 43-year-old male alcoholic\"]], \"start\": [[8]], \"entity_id\": [\"T3\"], \"Age\": {\"text\": [[\"43-year-old\"]], \"start\": [[10]], \"entity_id\": [\"T7\"]}, \"Gender\": {\"text\": [[\"male\"]], \"start\": [[22]], \"entity_id\": [\"T8\"]}}, \"Treatment\": {\"text\": [[\"completely abstinent with cyanamide treatment for 5 years\"]], \"start\": [[46]], \"entity_id\": [\"T4\"], \"Disorder\": {\"text\": [[\"alcoholic\"]], \"start\": [[27]], \"entity_id\": [\"T9\"]}, \"Drug\": {\"text\": [[\"cyanamide\"]], \"start\": [[72]], \"entity_id\": [\"T10\"]}, \"Duration\": {\"text\": [[\"5 years\"]], \"start\": [[96]], \"entity_id\": [\"T11\"]}}, \"Effect\": {\"text\": [[\"general fatigue\"]], \"start\": [[122]], \"entity_id\": [\"T6\"]}}"
}
]
}
] |
9042097_1 | Delayed hypersensitivity to flurbiprofen. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"to\"]], \"start\": [[25]], \"entity_id\": [\"T4\"]}, \"Effect\": {\"text\": [[\"Delayed hypersensitivity\"]], \"start\": [[0]], \"entity_id\": [\"T3\"]}, \"Treatment\": {\"text\": [[\"flurbiprofen\"]], \"start\": [[28]], \"entity_id\": [\"T5\"], \"Drug\": {\"text\": [[\"flurbiprofen\"]], \"start\": [[28]], \"entity_id\": [\"T6\"]}}}"
}
]
}
] |
10981493_3 | Propafenone-induced ataxia: report of three cases. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"induced\"]], \"start\": [[12]], \"entity_id\": [\"T5\"]}, \"Effect\": {\"text\": [[\"ataxia\"]], \"start\": [[20]], \"entity_id\": [\"T3\"]}, \"Treatment\": {\"text\": [[\"Propafenone\"]], \"start\": [[0]], \"entity_id\": [\"T4\"], \"Drug\": {\"text\": [[\"Propafenone\"]], \"start\": [[0]], \"entity_id\": [\"T8\"]}}, \"Subject\": {\"text\": [[\"three cases\"]], \"start\": [[38]], \"entity_id\": [\"T6\"], \"Population\": {\"text\": [[\"three\"]], \"start\": [[38]], \"entity_id\": [\"T7\"]}}}"
}
]
}
] |
11225565_6 | Delavirdine and efavirenz (but not nevirapine) also were strong inhibitors of CYP3A, consistent with clinical hazards of initial cotreatment with either of these drugs and substrates of CYP3A. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"consistent with\"]], \"start\": [[85]], \"entity_id\": [\"T12\"]}, \"Treatment\": {\"text\": [[\"Delavirdine and efavirenz (but not nevirapine)\"]], \"start\": [[0]], \"entity_id\": [\"T10\"], \"Drug\": {\"text\": [[\"Delavirdine\"], [\"efavirenz\"]], \"start\": [[0], [16]], \"entity_id\": [\"T14\", \"T13\"]}}, \"Effect\": {\"text\": [[\"clinical hazards\"]], \"start\": [[101]], \"entity_id\": [\"T11\"]}}"
}
]
}
] |
10688731_2 | This is the first report of UFT-induced scleroderma-like reaction. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"induced\"]], \"start\": [[32]], \"entity_id\": [\"T5\"]}, \"Treatment\": {\"text\": [[\"UFT\"]], \"start\": [[28]], \"entity_id\": [\"T3\"], \"Drug\": {\"text\": [[\"UFT\"]], \"start\": [[28]], \"entity_id\": [\"T6\"]}}, \"Effect\": {\"text\": [[\"scleroderma-like reaction\"]], \"start\": [[40]], \"entity_id\": [\"T4\"]}}"
}
]
}
] |
14526130_1 | Can roxithromycin and betamethasone induce acute pancreatitis? A case report. | true | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"induce\"]], \"start\": [[36]], \"entity_id\": [\"T5\"]}, \"Treatment\": {\"text\": [[\"roxithromycin and betamethasone\"]], \"start\": [[4]], \"entity_id\": [\"T4\"], \"Drug\": {\"text\": [[\"roxithromycin\"], [\"betamethasone\"]], \"start\": [[4], [22]], \"entity_id\": [\"T8\", \"T9\"]}, \"Combination\": [{\"event_id\": \"E2\", \"event_type\": \"Combination\", \"Trigger\": {\"text\": [[\"and\"]], \"start\": [[18]], \"entity_id\": [\"T10\"]}, \"Drug\": {\"text\": [[\"roxithromycin\"], [\"betamethasone\"]], \"start\": [[4], [22]], \"entity_id\": [\"T8\", \"T9\"]}}]}, \"Effect\": {\"text\": [[\"acute pancreatitis\"]], \"start\": [[43]], \"entity_id\": [\"T6\"]}, \"Speculated\": {\"text\": [[\"?\"]], \"start\": [[61]], \"entity_id\": [\"T7\"], \"value\": true}}"
}
]
}
] |
18362995_3 | Up to four percent of patients treated with imatinib may develop hepatotoxicity, which usually resolves with discontinuation of the drug. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"develop\"]], \"start\": [[57]], \"entity_id\": [\"T6\"]}, \"Subject\": {\"text\": [[\"Up to four percent of patients\"]], \"start\": [[0]], \"entity_id\": [\"T3\"], \"Population\": {\"text\": [[\"Up to four percent\"]], \"start\": [[0]], \"entity_id\": [\"T7\"]}}, \"Treatment\": {\"text\": [[\"imatinib\"]], \"start\": [[44]], \"entity_id\": [\"T4\"], \"Drug\": {\"text\": [[\"imatinib\"]], \"start\": [[44]], \"entity_id\": [\"T8\"]}}, \"Effect\": {\"text\": [[\"hepatotoxicity\"]], \"start\": [[65]], \"entity_id\": [\"T5\"]}, \"Speculated\": {\"text\": [[\"may\"]], \"start\": [[53]], \"entity_id\": [\"T9\"], \"value\": true}}"
}
]
}
] |
12923827_1 | Schneiderian first-rank symptoms associated with fluvoxamine treatment: a case report. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"associated\"]], \"start\": [[33]], \"entity_id\": [\"T3\"]}, \"Treatment\": {\"text\": [[\"fluvoxamine\"]], \"start\": [[49]], \"entity_id\": [\"T4\"], \"Drug\": {\"text\": [[\"fluvoxamine\"]], \"start\": [[49]], \"entity_id\": [\"T6\"]}}, \"Effect\": {\"text\": [[\"Schneiderian first-rank symptoms\"]], \"start\": [[0]], \"entity_id\": [\"T5\"]}}"
}
]
}
] |
17655517_5 | Peripheral and optic neuropathy was usually seen after several months of linezolid therapy (median 5 mo), lactic acidosis after several weeks (median 6 wks), and serotonin syndrome after several days (median 4 days). | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"after\"]], \"start\": [[49]], \"entity_id\": [\"T11\"]}, \"Effect\": {\"text\": [[\"Peripheral and optic neuropathy\", \"lactic acidosis after several weeks (median 6 wks), and serotonin syndrome after several days (median 4 days)\"]], \"start\": [[0, 106]], \"entity_id\": [\"T10\"]}, \"Treatment\": {\"text\": [[\"several months of linezolid therapy (median 5 mo)\"]], \"start\": [[55]], \"entity_id\": [\"T12\"], \"Drug\": {\"text\": [[\"linezolid\"]], \"start\": [[73]], \"entity_id\": [\"T14\"]}, \"Time_elapsed\": {\"text\": [[\"several months\"]], \"start\": [[55]], \"entity_id\": [\"T15\"]}}}"
}
]
}
] |
1849334_1 | Muzolimine-induced severe neuromyeloencephalopathy: report of seven cases. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"induced\"]], \"start\": [[11]], \"entity_id\": [\"T5\"]}, \"Treatment\": {\"text\": [[\"Muzolimine\"]], \"start\": [[0]], \"entity_id\": [\"T4\"], \"Dosage\": {\"text\": [[\"Muzolimine\"]], \"start\": [[0]], \"entity_id\": [\"T7\"]}}, \"Effect\": {\"text\": [[\"neuromyeloencephalopathy\"]], \"start\": [[26]], \"entity_id\": [\"T6\"]}, \"Severity\": {\"text\": [[\"severe\"]], \"start\": [[19]], \"entity_id\": [\"T8\"], \"value\": \"High\"}}"
}
]
}
] |
15494638_16 | We conclude peripheral neuropathy with 5-FU is rare. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"with\"]], \"start\": [[34]], \"entity_id\": [\"T6\"]}, \"Effect\": {\"text\": [[\"peripheral neuropathy\"]], \"start\": [[12]], \"entity_id\": [\"T5\"]}, \"Treatment\": {\"text\": [[\"5-FU\"]], \"start\": [[39]], \"entity_id\": [\"T7\"], \"Drug\": {\"text\": [[\"5-FU\"]], \"start\": [[39]], \"entity_id\": [\"T8\"]}}, \"Speculated\": {\"text\": [[\"rare\"]], \"start\": [[47]], \"entity_id\": [\"T9\"], \"value\": true}}"
}
]
}
] |
7962394_2 | Additionally, danazol produces hepatocellular damage in approximately 10% of women. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"produces\"]], \"start\": [[22]], \"entity_id\": [\"T4\"]}, \"Treatment\": {\"text\": [[\"danazol\"]], \"start\": [[14]], \"entity_id\": [\"T3\"], \"Drug\": {\"text\": [[\"danazol\"]], \"start\": [[14]], \"entity_id\": [\"T9\"]}}, \"Effect\": {\"text\": [[\"hepatocellular damage\"]], \"start\": [[31]], \"entity_id\": [\"T5\"]}, \"Subject\": {\"text\": [[\"10% of women\"]], \"start\": [[70]], \"entity_id\": [\"T6\"], \"Population\": {\"text\": [[\"10%\"]], \"start\": [[70]], \"entity_id\": [\"T7\"]}, \"Gender\": {\"text\": [[\"women\"]], \"start\": [[77]], \"entity_id\": [\"T8\"]}}}"
}
]
}
] |
17188061_1 | CONCLUSIONS: We report a typical symptoms of Charles-Bonnet syndrome (CBS) in patients with severe AMD after intravitreal Avastin-injections. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"after\"]], \"start\": [[103]], \"entity_id\": [\"T7\"]}, \"Effect\": {\"text\": [[\"typical symptoms of Charles-Bonnet syndrome (CBS)\"]], \"start\": [[25]], \"entity_id\": [\"T5\"]}, \"Subject\": {\"text\": [[\"patients with severe AMD\"]], \"start\": [[78]], \"entity_id\": [\"T6\"]}, \"Treatment\": {\"text\": [[\"intravitreal Avastin-injections\"]], \"start\": [[109]], \"entity_id\": [\"T8\"], \"Drug\": {\"text\": [[\"Avastin\"]], \"start\": [[122]], \"entity_id\": [\"T10\"]}, \"Route\": {\"text\": [[\"intravitreal\", \"injections\"]], \"start\": [[109, 130]], \"entity_id\": [\"T11\"]}, \"Disorder\": {\"text\": [[\"AMD\"]], \"start\": [[99]], \"entity_id\": [\"T12\"]}}}"
}
]
}
] |
11033734_3 | Proconvulsive tendency of imipenem/cilastatin is one of its well-known side effects. | true | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"side effects\"]], \"start\": [[71]], \"entity_id\": [\"T6\"]}, \"Treatment\": {\"text\": [[\"imipenem/cilastatin\"]], \"start\": [[26]], \"entity_id\": [\"T4\"], \"Drug\": {\"text\": [[\"cilastatin\"], [\"imipenem\"]], \"start\": [[35], [26]], \"entity_id\": [\"T7\", \"T8\"]}, \"Combination\": [{\"event_id\": \"E2\", \"event_type\": \"Combination\", \"Trigger\": {\"text\": [[\"/\"]], \"start\": [[34]], \"entity_id\": [\"T9\"]}, \"Drug\": {\"text\": [[\"imipenem\"], [\"cilastatin\"]], \"start\": [[26], [35]], \"entity_id\": [\"T8\", \"T7\"]}}]}, \"Effect\": {\"text\": [[\"Proconvulsive tendency\"]], \"start\": [[0]], \"entity_id\": [\"T5\"]}}"
}
]
}
] |
9013348_1 | A 49-year-old man with Crohn's disease treated with prednisone and mesalamine (5-ASA) developed worsening respiratory distress and fever. | true | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"developed\"]], \"start\": [[86]], \"entity_id\": [\"T10\"]}, \"Subject\": {\"text\": [[\"49-year-old man with Crohn's disease\"]], \"start\": [[2]], \"entity_id\": [\"T9\"], \"Age\": {\"text\": [[\"49-year-old\"]], \"start\": [[2]], \"entity_id\": [\"T13\"]}, \"Gender\": {\"text\": [[\"man\"]], \"start\": [[14]], \"entity_id\": [\"T14\"]}}, \"Effect\": {\"text\": [[\"worsening respiratory distress and fever.\"]], \"start\": [[96]], \"entity_id\": [\"T11\"]}, \"Treatment\": {\"text\": [[\"prednisone and mesalamine (5-ASA)\"]], \"start\": [[52]], \"entity_id\": [\"T12\"], \"Disorder\": {\"text\": [[\"Crohn's disease\"]], \"start\": [[23]], \"entity_id\": [\"T16\"]}, \"Drug\": {\"text\": [[\"mesalamine\"], [\"prednisone\"]], \"start\": [[67], [52]], \"entity_id\": [\"T19\", \"T20\"]}, \"Combination\": [{\"event_id\": \"E2\", \"event_type\": \"Combination\", \"Trigger\": {\"text\": [[\"and\"]], \"start\": [[63]], \"entity_id\": [\"T18\"]}, \"Drug\": {\"text\": [[\"prednisone\"], [\"mesalamine\"]], \"start\": [[52], [67]], \"entity_id\": [\"T20\", \"T19\"]}}]}, \"Severity\": {\"text\": [[\"worsening\"]], \"start\": [[96]], \"entity_id\": [\"T17\"], \"value\": \"Medium\"}}"
}
]
}
] |
18721173_3 | OBJECTIVE: This case report outlines a significant type of morbidity due to continued use of gabapentin during an episode of acute renal failure. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"use\"]], \"start\": [[86]], \"entity_id\": [\"T3\"]}, \"Treatment\": {\"text\": [[\"gabapentin\"]], \"start\": [[93]], \"entity_id\": [\"T4\"], \"Drug\": {\"text\": [[\"gabapentin\"]], \"start\": [[93]], \"entity_id\": [\"T7\"]}}, \"Effect\": {\"text\": [[\"a significant type of morbidity\"]], \"start\": [[37]], \"entity_id\": [\"T5\"]}, \"Subject\": {\"text\": [[\"This case\"]], \"start\": [[11]], \"entity_id\": [\"T6\"]}}"
}
]
}
] |
18585545_1 | Acute delirium resulting from levofloxacin therapy is an exceedingly rare complication that has been thought to occur more commonly in elderly patients. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"resulting\"]], \"start\": [[15]], \"entity_id\": [\"T4\"]}, \"Subject\": {\"text\": [[\"elderly patients\"]], \"start\": [[135]], \"entity_id\": [\"T3\"], \"Age\": {\"text\": [[\"elderly\"]], \"start\": [[135]], \"entity_id\": [\"T7\"]}}, \"Effect\": {\"text\": [[\"Acute delirium\"]], \"start\": [[0]], \"entity_id\": [\"T5\"]}, \"Treatment\": {\"text\": [[\"levofloxacin\"]], \"start\": [[30]], \"entity_id\": [\"T6\"], \"Drug\": {\"text\": [[\"levofloxacin\"]], \"start\": [[30]], \"entity_id\": [\"T9\"]}}, \"Speculated\": {\"text\": [[\"exceedingly rare\"]], \"start\": [[57]], \"entity_id\": [\"T8\"], \"value\": true}}"
}
]
}
] |
17473493_1 | Selective estrogen receptor modulator raloxifene-associated aggravation of nonalcoholic steatohepatitis. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"associated\"]], \"start\": [[49]], \"entity_id\": [\"T4\"]}, \"Treatment\": {\"text\": [[\"raloxifene\"]], \"start\": [[38]], \"entity_id\": [\"T3\"], \"Drug\": {\"text\": [[\"raloxifene\"]], \"start\": [[38]], \"entity_id\": [\"T6\"]}}, \"Effect\": {\"text\": [[\"aggravation of nonalcoholic steatohepatitis\"]], \"start\": [[60]], \"entity_id\": [\"T5\"]}}"
}
]
}
] |
15162903_4 | The day after methotrexate administration, the patient complained of severe back pain and urinary retention. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"complained\"]], \"start\": [[55]], \"entity_id\": [\"T6\"]}, \"Treatment\": {\"text\": [[\"The day after methotrexate administration\"]], \"start\": [[0]], \"entity_id\": [\"T5\"], \"Drug\": {\"text\": [[\"methotrexate\"]], \"start\": [[14]], \"entity_id\": [\"T8\"]}, \"Time_elapsed\": {\"text\": [[\"The day after\"]], \"start\": [[0]], \"entity_id\": [\"T9\"]}}, \"Effect\": {\"text\": [[\"severe back pain and urinary retention\"]], \"start\": [[69]], \"entity_id\": [\"T7\"]}}"
}
]
}
] |
11943900_1 | Pulmonary toxicity secondary to procarbazine. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"secondary\"]], \"start\": [[19]], \"entity_id\": [\"T5\"]}, \"Effect\": {\"text\": [[\"Pulmonary toxicity\"]], \"start\": [[0]], \"entity_id\": [\"T3\"]}, \"Treatment\": {\"text\": [[\"procarbazine\"]], \"start\": [[32]], \"entity_id\": [\"T4\"], \"Drug\": {\"text\": [[\"procarbazine\"]], \"start\": [[32]], \"entity_id\": [\"T6\"]}}}"
}
]
}
] |
58443_1 | In keeping with findings in the literature, the aortic wall in this case was damaged by secondary changes following irradiation and Bleomycin treatment. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"following\"]], \"start\": [[106]], \"entity_id\": [\"T5\"]}, \"Effect\": {\"text\": [[\"aortic wall in this case was damaged\"]], \"start\": [[48]], \"entity_id\": [\"T3\"]}, \"Treatment\": {\"text\": [[\"irradiation and Bleomycin treatment.\"]], \"start\": [[116]], \"entity_id\": [\"T4\"], \"Drug\": {\"text\": [[\"Bleomycin\"]], \"start\": [[132]], \"entity_id\": [\"T6\"]}}}"
}
]
}
] |
12460237_3 | It has been suggested that PPE caused by cytarabine does not recur with subsequent cytarabine re-challenge. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"caused\"]], \"start\": [[31]], \"entity_id\": [\"T9\"]}, \"Effect\": {\"text\": [[\"PPE\"]], \"start\": [[27]], \"entity_id\": [\"T8\"]}, \"Treatment\": {\"text\": [[\"cytarabine\"]], \"start\": [[41]], \"entity_id\": [\"T10\"], \"Drug\": {\"text\": [[\"cytarabine\"]], \"start\": [[41]], \"entity_id\": [\"T11\"]}}, \"Negated\": {\"text\": [[\"not\"]], \"start\": [[57]], \"entity_id\": [\"T12\"], \"value\": true}}"
}
]
}
] |
9205466_3 | CONCLUSIONS: The value of multihormonal therapy in breast carcinoma is not established, and the addition of progestogens to tamoxifen may not reduce of developing endometrial lesions, including carcinoma. | true | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"may not reduce\"]], \"start\": [[134]], \"entity_id\": [\"T6\"]}, \"Effect\": {\"text\": [[\"endometrial lesions\"], [\"carcinoma\"]], \"start\": [[163], [194]], \"entity_id\": [\"T7\", \"T8\"]}, \"Treatment\": {\"text\": [[\"addition of progestogens to tamoxifen\"]], \"start\": [[96]], \"entity_id\": [\"T5\"], \"Drug\": {\"text\": [[\"progestogens\"], [\"tamoxifen\"]], \"start\": [[108], [124]], \"entity_id\": [\"T10\", \"T11\"]}, \"Combination\": [{\"event_id\": \"E2\", \"event_type\": \"Combination\", \"Trigger\": {\"text\": [[\"addition\"]], \"start\": [[96]], \"entity_id\": [\"T12\"]}, \"Drug\": {\"text\": [[\"progestogens\"], [\"tamoxifen\"]], \"start\": [[108], [124]], \"entity_id\": [\"T10\", \"T11\"]}}]}, \"Speculated\": {\"text\": [[\"may\"]], \"start\": [[134]], \"entity_id\": [\"T9\"], \"value\": true}}"
}
]
}
] |
426502_2 | Inappropriate antidiuretic hormone following adenine arabinoside administration. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"following\"]], \"start\": [[35]], \"entity_id\": [\"T4\"]}, \"Effect\": {\"text\": [[\"Inappropriate antidiuretic hormone\"]], \"start\": [[0]], \"entity_id\": [\"T3\"]}, \"Treatment\": {\"text\": [[\"adenine arabinoside\"]], \"start\": [[45]], \"entity_id\": [\"T5\"], \"Drug\": {\"text\": [[\"adenine arabinoside\"]], \"start\": [[45]], \"entity_id\": [\"T6\"]}}}"
}
]
}
] |
6484655_2 | Ampicillin-associated seizures. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"associated\"]], \"start\": [[11]], \"entity_id\": [\"T3\"]}, \"Treatment\": {\"text\": [[\"Ampicillin\"]], \"start\": [[0]], \"entity_id\": [\"T4\"], \"Drug\": {\"text\": [[\"Ampicillin\"]], \"start\": [[0]], \"entity_id\": [\"T6\"]}}, \"Effect\": {\"text\": [[\"seizures\"]], \"start\": [[22]], \"entity_id\": [\"T5\"]}}"
}
]
}
] |
6692713_4 | We describe a case of fibrosing alveolitis, diagnosed by lung biopsy, in a patient receiving amiodarone which responded to corticosteroid therapy. | true | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"receiving\"]], \"start\": [[83]], \"entity_id\": [\"T7\"]}, \"Effect\": {\"text\": [[\"fibrosing alveolitis\"]], \"start\": [[22]], \"entity_id\": [\"T4\"]}, \"Subject\": {\"text\": [[\"a patient\"]], \"start\": [[73]], \"entity_id\": [\"T6\"]}, \"Treatment\": {\"text\": [[\"amiodarone which responded to corticosteroid therapy\"]], \"start\": [[93]], \"entity_id\": [\"T8\"], \"Drug\": {\"text\": [[\"amiodarone\"], [\"corticosteroid\"]], \"start\": [[93], [123]], \"entity_id\": [\"T5\", \"T9\"]}, \"Combination\": [{\"event_id\": \"E2\", \"event_type\": \"Combination\", \"Trigger\": {\"text\": [[\"responded\"]], \"start\": [[110]], \"entity_id\": [\"T3\"]}, \"Drug\": {\"text\": [[\"amiodarone\"], [\"corticosteroid\"]], \"start\": [[93], [123]], \"entity_id\": [\"T5\", \"T9\"]}}]}}"
}
]
}
] |
7752014_1 | Furosemide-associated fever. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"associated\"]], \"start\": [[11]], \"entity_id\": [\"T5\"]}, \"Treatment\": {\"text\": [[\"Furosemide\"]], \"start\": [[0]], \"entity_id\": [\"T4\"], \"Drug\": {\"text\": [[\"Furosemide\"]], \"start\": [[0]], \"entity_id\": [\"T7\"]}}, \"Effect\": {\"text\": [[\"fever\"]], \"start\": [[22]], \"entity_id\": [\"T6\"]}}"
}
]
}
] |
18810448_2 | Thymic enlargement in a patient with juvenile idiopathic arthritis during etanercept therapy. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"during\"]], \"start\": [[67]], \"entity_id\": [\"T5\"]}, \"Effect\": {\"text\": [[\"Thymic enlargement\"]], \"start\": [[0]], \"entity_id\": [\"T3\"]}, \"Subject\": {\"text\": [[\"a patient with juvenile idiopathic arthritis\"]], \"start\": [[22]], \"entity_id\": [\"T4\"], \"Age\": {\"text\": [[\"juvenile\"]], \"start\": [[37]], \"entity_id\": [\"T2\"]}}, \"Treatment\": {\"text\": [[\"etanercept\"]], \"start\": [[74]], \"entity_id\": [\"T6\"], \"Drug\": {\"text\": [[\"etanercept\"]], \"start\": [[74]], \"entity_id\": [\"T8\"]}, \"Disorder\": {\"text\": [[\"idiopathic arthritis\"]], \"start\": [[46]], \"entity_id\": [\"T1\"]}}}"
}
]
}
] |
24846936_1 | Fatal methylene blue associated serotonin toxicity. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"associated\"]], \"start\": [[21]], \"entity_id\": [\"T5\"]}, \"Treatment\": {\"text\": [[\"methylene blue\"]], \"start\": [[6]], \"entity_id\": [\"T4\"], \"Drug\": {\"text\": [[\"methylene blue\"]], \"start\": [[6]], \"entity_id\": [\"T7\"]}}, \"Effect\": {\"text\": [[\"serotonin toxicity\"]], \"start\": [[32]], \"entity_id\": [\"T6\"]}, \"Severity\": {\"text\": [[\"Fatal\"]], \"start\": [[0]], \"entity_id\": [\"T8\"], \"value\": \"High\"}}"
}
]
}
] |
7900744_4 | Mannitol-induced ARF responds promptly to hemodialysis with rapid resolution of anuria and recovery of renal failure. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"induced\"]], \"start\": [[9]], \"entity_id\": [\"T3\"]}, \"Effect\": {\"text\": [[\"ARF\", \"anuria\", \"renal failure\"]], \"start\": [[17, 80, 103]], \"entity_id\": [\"T5\"]}, \"Treatment\": {\"text\": [[\"Mannitol\"]], \"start\": [[0]], \"entity_id\": [\"T4\"], \"Drug\": {\"text\": [[\"Mannitol\"]], \"start\": [[0]], \"entity_id\": [\"T6\"]}}}"
}
]
}
] |
18665833_3 | We report a rare case of recurrent (stuttering) priapism in a patient with protein C deficiency while maintained on Warfarin therapy. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"while\"]], \"start\": [[96]], \"entity_id\": [\"T5\"]}, \"Effect\": {\"text\": [[\"recurrent (stuttering) priapism\"]], \"start\": [[25]], \"entity_id\": [\"T6\"]}, \"Subject\": {\"text\": [[\"a patient with protein C deficiency\"]], \"start\": [[60]], \"entity_id\": [\"T7\"]}, \"Treatment\": {\"text\": [[\"maintained on Warfarin therapy\"]], \"start\": [[102]], \"entity_id\": [\"T8\"], \"Disorder\": {\"text\": [[\"protein C deficiency\"]], \"start\": [[75]], \"entity_id\": [\"T9\"]}, \"Drug\": {\"text\": [[\"Warfarin\"]], \"start\": [[116]], \"entity_id\": [\"T10\"]}}}"
}
]
}
] |
16641839_1 | Angioedema and maculopapular eruptions associated with carbamazepine administration. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"associated\"]], \"start\": [[39]], \"entity_id\": [\"T6\"]}, \"Effect\": {\"text\": [[\"Angioedema and maculopapular eruptions\"]], \"start\": [[0]], \"entity_id\": [\"T5\"]}, \"Treatment\": {\"text\": [[\"carbamazepine administration.\"]], \"start\": [[55]], \"entity_id\": [\"T7\"], \"Drug\": {\"text\": [[\"carbamazepine\"]], \"start\": [[55]], \"entity_id\": [\"T8\"]}}}"
}
]
}
] |
9195619_2 | Mental nerve neuropathy as a result of hepatitis B vaccination. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"result\"]], \"start\": [[29]], \"entity_id\": [\"T4\"]}, \"Treatment\": {\"text\": [[\"hepatitis B vaccination\"]], \"start\": [[39]], \"entity_id\": [\"T3\"], \"Drug\": {\"text\": [[\"hepatitis B vaccination.\"]], \"start\": [[39]], \"entity_id\": [\"T6\"]}}, \"Effect\": {\"text\": [[\"Mental nerve neuropathy\"]], \"start\": [[0]], \"entity_id\": [\"T5\"]}}"
}
]
}
] |
12860350_2 | We describe a premenopausal woman who, while having tamoxifen due to a diagnosis of in situ ductal carcinoma, developed endometriosis requiring surgery. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"developed\"]], \"start\": [[110]], \"entity_id\": [\"T5\"]}, \"Subject\": {\"text\": [[\"a premenopausal woman\"]], \"start\": [[12]], \"entity_id\": [\"T3\"], \"Gender\": {\"text\": [[\"woman\"]], \"start\": [[28]], \"entity_id\": [\"T9\"]}, \"Age\": {\"text\": [[\"premenopausal\"]], \"start\": [[14]], \"entity_id\": [\"T10\"]}}, \"Treatment\": {\"text\": [[\"tamoxifen\"]], \"start\": [[52]], \"entity_id\": [\"T6\"], \"Drug\": {\"text\": [[\"tamoxifen\"]], \"start\": [[52]], \"entity_id\": [\"T12\"]}, \"Disorder\": {\"text\": [[\"in situ ductal carcinoma\"]], \"start\": [[84]], \"entity_id\": [\"T13\"]}}, \"Effect\": {\"text\": [[\"endometriosis\"]], \"start\": [[120]], \"entity_id\": [\"T7\"]}, \"Severity\": {\"text\": [[\"requiring surgery\"]], \"start\": [[134]], \"entity_id\": [\"T8\"], \"value\": \"Medium\"}}"
}
]
}
] |
12773807_1 | Disseminated cellulitic cryptococcosis in the setting of prednisone monotherapy for pemphigus vulgaris. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"in the setting of\"]], \"start\": [[39]], \"entity_id\": [\"T6\"]}, \"Effect\": {\"text\": [[\"Disseminated cellulitic cryptococcosis\"]], \"start\": [[0]], \"entity_id\": [\"T3\"]}, \"Treatment\": {\"text\": [[\"prednisone monotherapy\"]], \"start\": [[57]], \"entity_id\": [\"T4\"], \"Drug\": {\"text\": [[\"prednisone\"]], \"start\": [[57]], \"entity_id\": [\"T7\"]}, \"Disorder\": {\"text\": [[\"pemphigus vulgaris\"]], \"start\": [[84]], \"entity_id\": [\"T8\"]}}}"
}
]
}
] |
3417739_2 | We describe a 63 year old woman with a suppurative mediastinitis, treated with continuous PI irrigation who developed an acute oliguric renal failure. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"developed\"]], \"start\": [[108]], \"entity_id\": [\"T6\"]}, \"Subject\": {\"text\": [[\"a 63 year old woman with a suppurative mediastinitis\"]], \"start\": [[12]], \"entity_id\": [\"T3\"], \"Age\": {\"text\": [[\"63 year old\"]], \"start\": [[14]], \"entity_id\": [\"T8\"]}, \"Gender\": {\"text\": [[\"woman\"]], \"start\": [[26]], \"entity_id\": [\"T9\"]}}, \"Treatment\": {\"text\": [[\"continuous PI irrigation\"]], \"start\": [[79]], \"entity_id\": [\"T5\"], \"Drug\": {\"text\": [[\"PI\"]], \"start\": [[90]], \"entity_id\": [\"T10\"]}, \"Disorder\": {\"text\": [[\"suppurative mediastinitis\"]], \"start\": [[39]], \"entity_id\": [\"T11\"]}, \"Route\": {\"text\": [[\"irrigation\"]], \"start\": [[93]], \"entity_id\": [\"T12\"]}}, \"Effect\": {\"text\": [[\"acute oliguric renal failure\"]], \"start\": [[121]], \"entity_id\": [\"T7\"]}}"
}
]
}
] |
3128415_1 | A young woman with epilepsy had tonic-clonic seizures during antineoplastic therapy with adriamycin and cisplatin. | true | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"had\"]], \"start\": [[28]], \"entity_id\": [\"T4\"]}, \"Treatment\": {\"text\": [[\"antineoplastic therapy with adriamycin and cisplatin.\"]], \"start\": [[61]], \"entity_id\": [\"T5\"], \"Drug\": {\"text\": [[\"adriamycin\"], [\"cisplatin\"]], \"start\": [[89], [104]], \"entity_id\": [\"T11\", \"T12\"]}, \"Disorder\": {\"text\": [[\"epilepsy\"]], \"start\": [[19]], \"entity_id\": [\"T14\"]}, \"Combination\": [{\"event_id\": \"E2\", \"event_type\": \"Combination\", \"Trigger\": {\"text\": [[\"and\"]], \"start\": [[100]], \"entity_id\": [\"T13\"]}, \"Drug\": {\"text\": [[\"adriamycin\"], [\"cisplatin\"]], \"start\": [[89], [104]], \"entity_id\": [\"T11\", \"T12\"]}}]}, \"Subject\": {\"text\": [[\"A young woman with epilepsy\"]], \"start\": [[0]], \"entity_id\": [\"T6\"], \"Age\": {\"text\": [[\"young\"]], \"start\": [[2]], \"entity_id\": [\"T8\"]}, \"Gender\": {\"text\": [[\"woman\"]], \"start\": [[8]], \"entity_id\": [\"T9\"]}}, \"Effect\": {\"text\": [[\"tonic-clonic seizures\"]], \"start\": [[32]], \"entity_id\": [\"T7\"]}}"
}
]
}
] |
19567656_1 | CONCLUSIONS: This patient's rhabdomyolysis was probably induced by sertraline therapy. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"induced\"]], \"start\": [[56]], \"entity_id\": [\"T5\"]}, \"Subject\": {\"text\": [[\"This patient\"]], \"start\": [[13]], \"entity_id\": [\"T3\"]}, \"Effect\": {\"text\": [[\"rhabdomyolysis\"]], \"start\": [[28]], \"entity_id\": [\"T4\"]}, \"Treatment\": {\"text\": [[\"sertraline\"]], \"start\": [[67]], \"entity_id\": [\"T6\"], \"Drug\": {\"text\": [[\"sertraline\"]], \"start\": [[67]], \"entity_id\": [\"T8\"]}}, \"Speculated\": {\"text\": [[\"probably\"]], \"start\": [[47]], \"entity_id\": [\"T7\"], \"value\": true}}"
}
]
}
] |
16225183_1 | Nephrotic syndrome in a multiple sclerosis patient treated with interferon beta 1a. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"treated\"]], \"start\": [[51]], \"entity_id\": [\"T11\"]}, \"Effect\": {\"text\": [[\"Nephrotic syndrome\"]], \"start\": [[0]], \"entity_id\": [\"T7\"]}, \"Subject\": {\"text\": [[\"a multiple sclerosis patient\"]], \"start\": [[22]], \"entity_id\": [\"T9\"]}, \"Treatment\": {\"text\": [[\"interferon beta 1a\"]], \"start\": [[64]], \"entity_id\": [\"T10\"], \"Drug\": {\"text\": [[\"interferon beta 1a\"]], \"start\": [[64]], \"entity_id\": [\"T12\"]}, \"Disorder\": {\"text\": [[\"multiple sclerosis\"]], \"start\": [[24]], \"entity_id\": [\"T13\"]}}}"
}
]
}
] |
7937287_8 | In our patient, DIAN possibly was related to cefuroxime, but the patient did not experience associated allergic symptoms. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"related to\"]], \"start\": [[34]], \"entity_id\": [\"T8\"]}, \"Treatment\": {\"text\": [[\"cefuroxime\"]], \"start\": [[45]], \"entity_id\": [\"T6\"], \"Drug\": {\"text\": [[\"cefuroxime\"]], \"start\": [[45]], \"entity_id\": [\"T10\"]}}, \"Effect\": {\"text\": [[\"DIAN\"]], \"start\": [[16]], \"entity_id\": [\"T7\"]}, \"Subject\": {\"text\": [[\"our patient\"]], \"start\": [[3]], \"entity_id\": [\"T9\"]}}"
}
]
}
] |
9642842_2 | We describe the case of a nonatopic 17-year-old girl with bronchial asthma and aspirin intolerance who developed a dramatic anaphylactic reaction to oral prednisone. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"developed\"]], \"start\": [[103]], \"entity_id\": [\"T4\"]}, \"Subject\": {\"text\": [[\"a nonatopic 17-year-old girl with bronchial asthma and aspirin intolerance\"]], \"start\": [[24]], \"entity_id\": [\"T3\"], \"Disorder\": {\"text\": [[\"nonatopic\"], [\"aspirin intolerance\"]], \"start\": [[26], [79]], \"entity_id\": [\"T7\", \"T11\"]}, \"Age\": {\"text\": [[\"17-year-old\"]], \"start\": [[36]], \"entity_id\": [\"T8\"]}, \"Gender\": {\"text\": [[\"girl\"]], \"start\": [[48]], \"entity_id\": [\"T9\"]}}, \"Effect\": {\"text\": [[\"a dramatic anaphylactic reaction\"]], \"start\": [[113]], \"entity_id\": [\"T5\"]}, \"Treatment\": {\"text\": [[\"oral prednisone\"]], \"start\": [[149]], \"entity_id\": [\"T6\"], \"Route\": {\"text\": [[\"oral\"]], \"start\": [[149]], \"entity_id\": [\"T12\"]}, \"Drug\": {\"text\": [[\"prednisone\"]], \"start\": [[154]], \"entity_id\": [\"T13\"]}, \"Disorder\": {\"text\": [[\"bronchial asthma\"]], \"start\": [[58]], \"entity_id\": [\"T14\"]}}}"
}
]
}
] |
10772434_1 | CASE SUMMARY: A 10-year-old white girl with bilateral optic glioma developed a hypersensitivity reaction to carboplatin after nine courses. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"developed\"]], \"start\": [[67]], \"entity_id\": [\"T4\"]}, \"Subject\": {\"text\": [[\"A 10-year-old white girl with bilateral optic glioma\"]], \"start\": [[14]], \"entity_id\": [\"T3\"], \"Age\": {\"text\": [[\"10-year-old\"]], \"start\": [[16]], \"entity_id\": [\"T7\"]}, \"Gender\": {\"text\": [[\"girl\"]], \"start\": [[34]], \"entity_id\": [\"T8\"]}, \"Race\": {\"text\": [[\"white\"]], \"start\": [[28]], \"entity_id\": [\"T9\"]}}, \"Effect\": {\"text\": [[\"hypersensitivity reaction\"]], \"start\": [[79]], \"entity_id\": [\"T5\"]}, \"Treatment\": {\"text\": [[\"carboplatin after nine courses\"]], \"start\": [[108]], \"entity_id\": [\"T6\"], \"Disorder\": {\"text\": [[\"bilateral optic glioma\"]], \"start\": [[44]], \"entity_id\": [\"T10\"]}, \"Drug\": {\"text\": [[\"carboplatin\"]], \"start\": [[108]], \"entity_id\": [\"T11\"]}, \"Duration\": {\"text\": [[\"nine courses\"]], \"start\": [[126]], \"entity_id\": [\"T12\"]}}}"
}
]
}
] |
18453852_16 | Liver function should be carefully monitored when rifampicin and lopinavir/ritonavir are combined in patients. | true | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"when\"]], \"start\": [[45]], \"entity_id\": [\"T9\"]}, \"Subject\": {\"text\": [[\"patients\"]], \"start\": [[101]], \"entity_id\": [\"T7\"]}, \"Effect\": {\"text\": [[\"Liver function should be carefully monitored\"]], \"start\": [[0]], \"entity_id\": [\"T6\"]}, \"Treatment\": {\"text\": [[\"rifampicin and lopinavir/ritonavir are combined\"]], \"start\": [[50]], \"entity_id\": [\"T8\"], \"Drug\": {\"text\": [[\"rifampicin\"], [\"lopinavir/ritonavir\"]], \"start\": [[50], [65]], \"entity_id\": [\"T12\", \"T13\"]}, \"Combination\": [{\"event_id\": \"E2\", \"event_type\": \"Combination\", \"Trigger\": {\"text\": [[\"and\"]], \"start\": [[61]], \"entity_id\": [\"T11\"]}, \"Drug\": {\"text\": [[\"rifampicin\"], [\"lopinavir/ritonavir\"]], \"start\": [[50], [65]], \"entity_id\": [\"T12\", \"T13\"]}}]}, \"Speculated\": {\"text\": [[\"monitored\"]], \"start\": [[35]], \"entity_id\": [\"T10\"], \"value\": true}}"
}
]
}
] |
15504988_2 | We report three patients, all of whom had preexisting diabetic dyslipidemia, who showed a profound reduction in plasma HDL cholesterol and apolipoprotein AI levels soon after the initiation of rosiglitazone therapy. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Potential_therapeutic_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Potential_therapeutic_event\", \"Trigger\": {\"text\": [[\"initiation\"]], \"start\": [[179]], \"entity_id\": [\"T7\"]}, \"Subject\": {\"text\": [[\"three patients\"]], \"start\": [[10]], \"entity_id\": [\"T3\"], \"Population\": {\"text\": [[\"three\"]], \"start\": [[10]], \"entity_id\": [\"T8\"]}}, \"Effect\": {\"text\": [[\"profound reduction in plasma HDL cholesterol and apolipoprotein AI levels\"]], \"start\": [[90]], \"entity_id\": [\"T5\"]}, \"Treatment\": {\"text\": [[\"rosiglitazone therapy\"]], \"start\": [[193]], \"entity_id\": [\"T6\"], \"Drug\": {\"text\": [[\"rosiglitazone\"]], \"start\": [[193]], \"entity_id\": [\"T9\"]}, \"Time_elapsed\": {\"text\": [[\"soon after\"]], \"start\": [[164]], \"entity_id\": [\"T10\"]}, \"Disorder\": {\"text\": [[\"preexisting diabetic dyslipidemia\"]], \"start\": [[42]], \"entity_id\": [\"T11\"]}}}"
}
]
}
] |
12923827_4 | This finding suggests that fluvoxamine can precipitate Schneiderian first-rank symptoms in some susceptible patients. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"precipitate\"]], \"start\": [[43]], \"entity_id\": [\"T4\"]}, \"Treatment\": {\"text\": [[\"fluvoxamine\"]], \"start\": [[27]], \"entity_id\": [\"T3\"], \"Drug\": {\"text\": [[\"fluvoxamine\"]], \"start\": [[27]], \"entity_id\": [\"T7\"]}}, \"Effect\": {\"text\": [[\"Schneiderian first-rank symptoms\"]], \"start\": [[55]], \"entity_id\": [\"T5\"]}, \"Subject\": {\"text\": [[\"some susceptible patients\"]], \"start\": [[91]], \"entity_id\": [\"T6\"]}, \"Speculated\": {\"text\": [[\"suggests\"]], \"start\": [[13]], \"entity_id\": [\"T8\"], \"value\": true}}"
}
]
}
] |
14960440_3 | Warfarin-associated thoracic aortic dissection in an elderly woman. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"associated\"]], \"start\": [[9]], \"entity_id\": [\"T3\"]}, \"Treatment\": {\"text\": [[\"Warfarin\"]], \"start\": [[0]], \"entity_id\": [\"T4\"], \"Drug\": {\"text\": [[\"Warfarin\"]], \"start\": [[0]], \"entity_id\": [\"T9\"]}}, \"Effect\": {\"text\": [[\"thoracic aortic dissection\"]], \"start\": [[20]], \"entity_id\": [\"T5\"]}, \"Subject\": {\"text\": [[\"an elderly woman\"]], \"start\": [[50]], \"entity_id\": [\"T6\"], \"Age\": {\"text\": [[\"elderly\"]], \"start\": [[53]], \"entity_id\": [\"T7\"]}, \"Gender\": {\"text\": [[\"woman\"]], \"start\": [[61]], \"entity_id\": [\"T8\"]}}}"
}
]
}
] |
10774758_2 | This is the first report of an adverse effect of fetal renal circulation by maternal ingestion of nimesulide. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"adverse effect\"]], \"start\": [[31]], \"entity_id\": [\"T5\"]}, \"Subject\": {\"text\": [[\"first report of an adverse effect of fetal renal circulation\"]], \"start\": [[12]], \"entity_id\": [\"T3\"]}, \"Treatment\": {\"text\": [[\"maternal ingestion of nimesulide\"], [\"nimesulide\"]], \"start\": [[76], [98]], \"entity_id\": [\"T4\", \"T6\"], \"Drug\": {\"text\": [[\"nimesulide\"]], \"start\": [[98]], \"entity_id\": [\"T8\"]}, \"Route\": {\"text\": [[\"maternal ingestion\"]], \"start\": [[76]], \"entity_id\": [\"T9\"]}}, \"Effect\": {\"text\": [[\"fetal renal circulation\"]], \"start\": [[49]], \"entity_id\": [\"T7\"]}}"
}
]
}
] |
11111942_1 | Diarrhea-associated over-anticoagulation in a patient taking warfarin: therapeutic role of cholestyramine. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"over-anticoagulation\"]], \"start\": [[20]], \"entity_id\": [\"T5\"]}, \"Treatment\": {\"text\": [[\"warfarin\"]], \"start\": [[61]], \"entity_id\": [\"T3\"], \"Drug\": {\"text\": [[\"warfarin\"]], \"start\": [[61]], \"entity_id\": [\"T7\"]}}, \"Effect\": {\"text\": [[\"Diarrhea-associated over-anticoagulation\"]], \"start\": [[0]], \"entity_id\": [\"T4\"]}, \"Subject\": {\"text\": [[\"patient\"]], \"start\": [[46]], \"entity_id\": [\"T6\"]}}"
}
]
}
] |
9876809_3 | A 72-year-old white man suddenly developed combative behavior, refused to leave his room, stopped eating, and began falling to the floor 6 weeks after being given ticlopidine. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"developed\"]], \"start\": [[33]], \"entity_id\": [\"T8\"]}, \"Subject\": {\"text\": [[\"A 72-year-old white man\"]], \"start\": [[0]], \"entity_id\": [\"T7\"], \"Age\": {\"text\": [[\"72-year-old\"]], \"start\": [[2]], \"entity_id\": [\"T11\"]}, \"Race\": {\"text\": [[\"white\"]], \"start\": [[14]], \"entity_id\": [\"T12\"]}, \"Gender\": {\"text\": [[\"man\"]], \"start\": [[20]], \"entity_id\": [\"T13\"]}}, \"Effect\": {\"text\": [[\"combative behavior, refused to leave his room, stopped eating, and began falling to the floor\"]], \"start\": [[43]], \"entity_id\": [\"T9\"]}, \"Treatment\": {\"text\": [[\"6 weeks after being given ticlopidine\"]], \"start\": [[137]], \"entity_id\": [\"T10\"], \"Time_elapsed\": {\"text\": [[\"6 weeks\"]], \"start\": [[137]], \"entity_id\": [\"T14\"]}, \"Drug\": {\"text\": [[\"ticlopidine\"]], \"start\": [[163]], \"entity_id\": [\"T15\"]}}}"
}
]
}
] |
71813_4 | The case history confirms that gold treatment, even in the same patient, can give rise to a wide range of skin disturbances, which in many cases do not break out until long after the drug has been withdrawn. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"give rise\"]], \"start\": [[77]], \"entity_id\": [\"T4\"]}, \"Treatment\": {\"text\": [[\"gold\"]], \"start\": [[31]], \"entity_id\": [\"T3\"], \"Drug\": {\"text\": [[\"gold\"]], \"start\": [[31]], \"entity_id\": [\"T7\"]}}, \"Effect\": {\"text\": [[\"wide range of skin disturbances, which in many cases do not break out until long after the drug has been withdrawn\"]], \"start\": [[92]], \"entity_id\": [\"T5\"]}, \"Subject\": {\"text\": [[\"in the same patient,\"]], \"start\": [[52]], \"entity_id\": [\"T6\"]}}"
}
]
}
] |
8828999_3 | Lithium neurotoxicity should be considered in Creutzfeldt-Jakob disease differential diagnosis, serial electroencephalograms being the most valuable. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"considered\"]], \"start\": [[32]], \"entity_id\": [\"T8\"]}, \"Treatment\": {\"text\": [[\"Lithium\"]], \"start\": [[0]], \"entity_id\": [\"T5\"], \"Disorder\": {\"text\": [[\"Creutzfeldt-Jakob disease\"]], \"start\": [[46]], \"entity_id\": [\"T7\"]}, \"Drug\": {\"text\": [[\"Lithium\"]], \"start\": [[0]], \"entity_id\": [\"T10\"]}}, \"Effect\": {\"text\": [[\"Lithium neurotoxicity\"]], \"start\": [[0]], \"entity_id\": [\"T6\"]}, \"Speculated\": {\"text\": [[\"should\"]], \"start\": [[22]], \"entity_id\": [\"T9\"], \"value\": true}}"
}
]
}
] |
7647084_1 | The authors describe a case of neuroleptic malignant syndrome that occurred in a patient on amitriptyline and lithium carbonate. | true | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"occurred\"]], \"start\": [[67]], \"entity_id\": [\"T6\"]}, \"Effect\": {\"text\": [[\"neuroleptic malignant syndrome\"]], \"start\": [[31]], \"entity_id\": [\"T4\"]}, \"Treatment\": {\"text\": [[\"amitriptyline and lithium carbonate\"]], \"start\": [[92]], \"entity_id\": [\"T7\"], \"Drug\": {\"text\": [[\"amitriptyline\"], [\"lithium carbonate\"]], \"start\": [[92], [110]], \"entity_id\": [\"T8\", \"T9\"]}, \"Combination\": [{\"event_id\": \"E2\", \"event_type\": \"Combination\", \"Trigger\": {\"text\": [[\"and\"]], \"start\": [[106]], \"entity_id\": [\"T10\"]}, \"Drug\": {\"text\": [[\"amitriptyline\"], [\"lithium carbonate\"]], \"start\": [[92], [110]], \"entity_id\": [\"T8\", \"T9\"]}}]}, \"Subject\": {\"text\": [[\"a patient\"]], \"start\": [[79]], \"entity_id\": [\"T5\"]}}"
}
]
}
] |
15239684_2 | The findings were judged to be consistent with soft-tissue injury associated with intravenous administration of phenytoin, also termed purple glove syndrome. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"associated\"]], \"start\": [[66]], \"entity_id\": [\"T5\"]}, \"Treatment\": {\"text\": [[\"intravenous administration of phenytoin\"]], \"start\": [[82]], \"entity_id\": [\"T6\"], \"Route\": {\"text\": [[\"ntravenous administration\"]], \"start\": [[83]], \"entity_id\": [\"T8\"]}, \"Drug\": {\"text\": [[\"phenytoin\"]], \"start\": [[112]], \"entity_id\": [\"T9\"]}}, \"Effect\": {\"text\": [[\"soft-tissue injury\"]], \"start\": [[47]], \"entity_id\": [\"T7\"]}}"
}
]
}
] |
10749332_1 | However, as illustrated by these and other cases reported to date, the onset of troglitazone-induced liver injury is insidious and temporally variable. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"induced\"]], \"start\": [[93]], \"entity_id\": [\"T3\"]}, \"Treatment\": {\"text\": [[\"troglitazone\"]], \"start\": [[80]], \"entity_id\": [\"T4\"], \"Drug\": {\"text\": [[\"troglitazone\"]], \"start\": [[80]], \"entity_id\": [\"T6\"]}}, \"Effect\": {\"text\": [[\"liver injury is insidious and temporally variable\"]], \"start\": [[101]], \"entity_id\": [\"T5\"]}}"
}
]
}
] |
2887555_1 | Soon after its introduction in 1952, chlorpromazine was noted to induce symptoms resembling Parkinson's disease. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"induce\"]], \"start\": [[65]], \"entity_id\": [\"T4\"]}, \"Treatment\": {\"text\": [[\"chlorpromazine\"]], \"start\": [[37]], \"entity_id\": [\"T3\"], \"Drug\": {\"text\": [[\"chlorpromazine\"]], \"start\": [[37]], \"entity_id\": [\"T6\"]}}, \"Effect\": {\"text\": [[\"symptoms resembling Parkinson's disease\"]], \"start\": [[72]], \"entity_id\": [\"T5\"]}}"
}
]
}
] |
9220046_4 | Erythromycin is a macrolide antibiotic that may increase the risk of lovastatin-induced rhabdomyolysis. | true | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"induced\"]], \"start\": [[80]], \"entity_id\": [\"T4\"]}, \"Treatment\": {\"text\": [[\"Erythromycin\"]], \"start\": [[0]], \"entity_id\": [\"T7\"], \"Drug\": {\"text\": [[\"Erythromycin\"], [\"lovastatin\"]], \"start\": [[0], [69]], \"entity_id\": [\"T8\", \"T9\"]}, \"Combination\": [{\"event_id\": \"E2\", \"event_type\": \"Combination\", \"Trigger\": {\"text\": [[\"risk\"]], \"start\": [[61]], \"entity_id\": [\"T10\"]}, \"Drug\": {\"text\": [[\"lovastatin\"], [\"Erythromycin\"]], \"start\": [[69], [0]], \"entity_id\": [\"T9\", \"T8\"]}}]}, \"Effect\": {\"text\": [[\"ncrease the risk of lovastatin-induced rhabdomyolysis\"]], \"start\": [[49]], \"entity_id\": [\"T5\"]}, \"Speculated\": {\"text\": [[\"may\"]], \"start\": [[44]], \"entity_id\": [\"T6\"], \"value\": true}}"
}
]
}
] |
17189581_3 | A 23-year-old white male patient was originally admitted to receive intravenous chemotherapy for acute myelogenous leukemia. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Potential_therapeutic_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Potential_therapeutic_event\", \"Trigger\": {\"text\": [[\"receive\"]], \"start\": [[60]], \"entity_id\": [\"T5\"]}, \"Treatment\": {\"text\": [[\"intravenous chemotherapy\"]], \"start\": [[68]], \"entity_id\": [\"T6\"], \"Drug\": {\"text\": [[\"chemotherapy\"]], \"start\": [[80]], \"entity_id\": [\"T12\"]}, \"Disorder\": {\"text\": [[\"acute myelogenous leukemia\"]], \"start\": [[97]], \"entity_id\": [\"T13\"]}, \"Route\": {\"text\": [[\"intravenous\"]], \"start\": [[68]], \"entity_id\": [\"T7\"]}}, \"Subject\": {\"text\": [[\"A 23-year-old white male patient\"]], \"start\": [[0]], \"entity_id\": [\"T8\"], \"Age\": {\"text\": [[\"23-year-old\"]], \"start\": [[2]], \"entity_id\": [\"T9\"]}, \"Race\": {\"text\": [[\"white\"]], \"start\": [[14]], \"entity_id\": [\"T10\"]}, \"Gender\": {\"text\": [[\"male\"]], \"start\": [[20]], \"entity_id\": [\"T11\"]}}}"
}
]
}
] |
2768785_2 | We present two children with acute lymphocytic leukemia who developed leukoencephalopathy following administration of a combination of intravenous ara = C and methotrexate during the consolidation phase of chemotherapy. | true | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"developed\"]], \"start\": [[60]], \"entity_id\": [\"T5\"]}, \"Subject\": {\"text\": [[\"two children with acute lymphocytic leukemia\"]], \"start\": [[11]], \"entity_id\": [\"T4\"], \"Population\": {\"text\": [[\"two\"]], \"start\": [[11]], \"entity_id\": [\"T8\"]}, \"Age\": {\"text\": [[\"children\"]], \"start\": [[15]], \"entity_id\": [\"T9\"]}}, \"Effect\": {\"text\": [[\"leukoencephalopathy\"]], \"start\": [[70]], \"entity_id\": [\"T6\"]}, \"Treatment\": {\"text\": [[\"administration of a combination of intravenous ara = C and methotrexate during the consolidation phase of chemotherapy\"]], \"start\": [[100]], \"entity_id\": [\"T7\"], \"Disorder\": {\"text\": [[\"acute lymphocytic leukemia\"]], \"start\": [[29]], \"entity_id\": [\"T10\"]}, \"Route\": {\"text\": [[\"intravenous\"]], \"start\": [[135]], \"entity_id\": [\"T12\"]}, \"Drug\": {\"text\": [[\"ara = C\"], [\"methotrexate\"]], \"start\": [[147], [159]], \"entity_id\": [\"T13\", \"T14\"]}, \"Combination\": [{\"event_id\": \"E2\", \"event_type\": \"Combination\", \"Trigger\": {\"text\": [[\"combination\"]], \"start\": [[120]], \"entity_id\": [\"T11\"]}, \"Drug\": {\"text\": [[\"ara = C\"], [\"methotrexate\"]], \"start\": [[147], [159]], \"entity_id\": [\"T13\", \"T14\"]}}]}}"
}
]
}
] |
2320800_1 | Lethal anuria complicating high dose ifosfamide chemotherapy in a breast cancer patient with an impaired renal function. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"complicating\"]], \"start\": [[14]], \"entity_id\": [\"T12\"]}, \"Subject\": {\"text\": [[\"a breast cancer patient with an impaired renal function\"]], \"start\": [[64]], \"entity_id\": [\"T9\"], \"Disorder\": {\"text\": [[\"an impaired renal function\"]], \"start\": [[93]], \"entity_id\": [\"T1\"]}}, \"Treatment\": {\"text\": [[\"high dose ifosfamide chemotherapy\"]], \"start\": [[27]], \"entity_id\": [\"T10\"], \"Disorder\": {\"text\": [[\"breast cancer\"]], \"start\": [[66]], \"entity_id\": [\"T13\"]}, \"Drug\": {\"text\": [[\"ifosfamide\"]], \"start\": [[37]], \"entity_id\": [\"T14\"]}, \"Route\": {\"text\": [[\"chemotherapy\"]], \"start\": [[48]], \"entity_id\": [\"T16\"]}, \"Dosage\": {\"text\": [[\"high dose\"]], \"start\": [[27]], \"entity_id\": [\"T17\"]}}, \"Effect\": {\"text\": [[\"anuria\"]], \"start\": [[7]], \"entity_id\": [\"T11\"]}, \"Severity\": {\"text\": [[\"Lethal\"]], \"start\": [[0]], \"entity_id\": [\"T15\"], \"value\": \"High\"}}"
}
]
}
] |
15013892_2 | CONCLUSIONS: Low dosages of quinacrine used for malaria prophylaxis can be associated with a delayed, severe maculopathy indistinguishable from chloroquine maculopathy in certain patients. | true | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"associated\"]], \"start\": [[75]], \"entity_id\": [\"T6\"]}, \"Effect\": {\"text\": [[\"a delayed, severe maculopathy\"]], \"start\": [[91]], \"entity_id\": [\"T8\"]}, \"Treatment\": {\"text\": [[\"Low dosages of quinacrine used for malaria prophylaxis\"]], \"start\": [[13]], \"entity_id\": [\"T7\"], \"Time_elapsed\": {\"text\": [[\"delayed\"]], \"start\": [[93]], \"entity_id\": [\"T10\"]}, \"Dosage\": {\"text\": [[\"Low dosages\"]], \"start\": [[13]], \"entity_id\": [\"T12\"]}, \"Drug\": {\"text\": [[\"quinacrine\"]], \"start\": [[28]], \"entity_id\": [\"T13\"]}, \"Disorder\": {\"text\": [[\"malaria prophylaxis\"]], \"start\": [[48]], \"entity_id\": [\"T14\"]}}, \"Severity\": {\"text\": [[\"severe\"]], \"start\": [[102]], \"entity_id\": [\"T9\"], \"value\": \"Medium\"}}"
},
{
"event_id": "E2",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E2\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"associated\"]], \"start\": [[75]], \"entity_id\": [\"T6\"]}, \"Treatment\": {\"text\": [[\"Low dosages of quinacrine used for malaria prophylaxis\"]], \"start\": [[13]], \"entity_id\": [\"T7\"], \"Time_elapsed\": {\"text\": [[\"delayed\"]], \"start\": [[93]], \"entity_id\": [\"T10\"]}, \"Dosage\": {\"text\": [[\"Low dosages\"]], \"start\": [[13]], \"entity_id\": [\"T12\"]}, \"Drug\": {\"text\": [[\"quinacrine\"]], \"start\": [[28]], \"entity_id\": [\"T13\"]}, \"Disorder\": {\"text\": [[\"malaria prophylaxis\"]], \"start\": [[48]], \"entity_id\": [\"T14\"]}}, \"Effect\": {\"text\": [[\"chloroquine maculopathy\"]], \"start\": [[144]], \"entity_id\": [\"T15\"]}, \"Subject\": {\"text\": [[\"certain patients.\"]], \"start\": [[171]], \"entity_id\": [\"T5\"]}}"
}
]
}
] |